Attention-deficit/hyperactivity disorder (ADHD) is a common but complex neurodevelopmental condition characterized by symptoms of inattention, hyperactivity, and ...
The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...
New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London has found that the effectiveness of ADHD medication may be associated with an individual's ...
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that causes hyperactivity and impulsivity in children and adults. If left untreated ...
Shorter wait times and lower costs. That’s what people with ADHD and their families can expect now Victorian GPs are getting ...
GlobalData on MSN
FDA accepts Otsuka’s centanafadine application for ADHD treatment
The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.
ADHD is a neurological condition that impacts millions of Australians, with estimates suggesting that between 6 and 10 percent of children and adolescents, and 2 to 6 percent of adults are affected.
In a groundbreaking move, the Allan government in Victoria has announced that general practitioners (GPs) will soon be able to diagnose and treat Attention Deficit Hyperactivity Disorder (ADHD) for ...
Boys who stopped ADHD treatment at higher risk for negative consequences. Oct. 16, 2012 — -- Young boys who discontinue treatment for attention deficit hyperactivity disorder (ADHD) are featured ...
General practitioners in Victoria will soon be able to diagnose and treat ADHD in adults and children in a move the state ...
ADHD New Zealand spokesperson Darrin Bull joins Mike Hosking to discuss the significant prescription law change that will make ADHD treatment easier to acc ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果